STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Cerebrolysin

Also known as

FPF 1070 · FPF-1070 · FPF1070 · Cerebrolysin concentrate · neuropeptide mixture (porcine) · brain protein hydrolysate (Cerebrolysin) · porcine brain-derived peptide preparation · EVER Pharma Cerebrolysin · Cerebrolysin® · cerebroprotein hydrolysate (related class — not identical to branded Cerebrolysin) · Renacenz (related cerebroprotein product discussions)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Systemic IM / IV Cognitive / nootropic peptides

An IM/IV porcine-brain peptide mixture with systemic exposure; not one receptor-specific peptide.

What people say Cerebrolysin is a prescription porcine-brain peptide and amino-acid preparation used by IM or IV in some countries for stroke, traumatic brain injury and dementia. It is not one synthetic peptide, an oral nootropic or U.S.-approved. Doses people talk about
Community pharma-ampoule reportsAbout 5 mL/day IM

Preserved nootropic/biohacker discussions describe this amount; self-reports do not establish benefit, safety or a personal regimen.

Community IV-access reportsAbout 5–10 mL/day total

This separate amount appears in IV-access discussions, not as an IM equivalent. Professional administration and product identity matter.

Official IM contextUp to 5 mL IM

Manufacturer dosage-card ceiling for undiluted clinical liquid under professional use.

Official IV contextsUp to 10 mL IV; 10–50 mL as infusion

Manufacturer document distinguishes smaller direct IV amounts from larger infusion volumes; no preparation steps are provided here.

The clinical liquid contains 215.2 mg concentrate per mL; it is not equivalent to research-powder mg charts. Indication-specific clinical courses and additional community logs remain in the dose notes.

Half-life & effect duration

Half-life in the body
  • Whole peptide mixtureNo single half-life
Felt duration people report
  • After an administrationSeveral hours of effects in some accounts; no acute cognitive change in others
  • Course / after-course reportsMood or sleep changes over weeks, later brain fog, or emotional flattening
Timing context & sources
How it may feel First-person logs are mixed: some report no immediate change, then sleep, mood or clarity changes; another described early euphoria and dreams followed by brain fog; another described a severe post-course mood crash. These are individual, heavily confounded accounts.
Cycles people discuss Official documents describe short daily courses for acute stroke or TBI and 4-week, five-days-per-week cycles for cognitive indications, sometimes repeated during the year. Forum re-runs vary and should not replace clinical supervision. Timing Morning use and AM/PM splits appear in nootropic charts, while some night users describe vivid dreams. Late-day stimulation or agitation leads some people to choose earlier use; learning or rehabilitation practice often accompanies the course. These are reported routines, not a controlled timing comparison. Stacks Semax, Selank, Dihexa, P21 and Pinealon appear in nootropic discussions. Stimulants, supplements, rehabilitation and other peptides make single-agent credit and adverse-effect attribution weak. Watch for Seizure risk / epilepsy: Product contraindications include epilepsy / major seizure disorders — risk of increasing seizure frequency is the stated concern.
Related
SemaxSelankDihexaP21Pinealon

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A single whole-product half-life was not established in the checked manufacturer monograph.

Cerebrolysin contains a mixture of low-molecular-weight peptides and amino acids rather than one parent molecule.

Manufacturer documentation is not an independent pharmacokinetic review; component-specific kinetics may differ and were not resolved here.

  • Cerebrolysin official product page (opens in a new tab)Prescribing-information section lines 41–67, including composition, prescription status, indications and contraindications.Manufacturer material; supports product identity and concentration but is not an independent efficacy or pharmacokinetic assessment.
  • Cerebrolysin Product Monograph 2021 (opens in a new tab)PDF page 77 Administration lines 2690–2709 and page 80 prescribing-information lines 2747–2773; full-document text search found no half-life or plasma entry.Manufacturer monograph; absence of a text-search hit is not proof that no component-specific pharmacokinetic literature exists elsewhere.

Felt duration people report

No dependable single-dose felt duration emerges from the inspected logs.

Accounts range from no acute cognitive change to effects described for several hours, week-scale mood or sleep changes, later brain fog, and a post-course anhedonia report.

Self-reports include stimulants, supplements, exercise, neurological conditions and uncertain product equivalence; severe outcomes cannot establish prevalence or causation.

  • Cerebrolysin experience log (opens in a new tab)Original-poster numbered updates lines 100–152; one-week follow-up lines 153–172; comments lines 203–257.Single changing self-log with ADHD, stimulant, concussion/alcohol history, sildenafil, thyroid medication and behavioral co-interventions; subjective persistence is not clearance.
  • Finished 20-day Cerebrolysin cycle (opens in a new tab)Original post lines 80–95; comments and follow-up lines 117–133.One self-report with exercise and many supplements; week-scale sequence and hours-long vision claim are not controlled or generalizable.
  • My first and only experience with Cerebrolysin (opens in a new tab)Original post lines 83–105; same-author replies lines 139–169.Single severe self-report using a product represented as equivalent to Cerebrolysin; product identity, co-use and causation are unresolved.

Other context in this card

What people say 14

  • Clarity / brain-fog anecdotes: Sharper recall, less fog, easier deep work, and “mental smoothness” are common healthy-user logs — confounded by sleep, placebo, and stacks. forum
  • Mood secondary: Some logs note steadier motivation or calmer baseline; not a primary labeled psychiatric indication. anecdote
  • Vivid dreams: Vendor/biohack write-ups and user logs sometimes list vivid dreaming as a course-time signal (plasticity lore) — not a controlled efficacy endpoint. anecdote
  • After-cycle persistence: Some claim benefits outlast daily dosing for days to weeks (plasticity story); others drop back quickly when the course ends. anecdote
  • Vs Semax/Selank: Cast as broader multi-week structural/repair course vs acute nasal “edge” tools — complementary roles in stack talk rather than pure substitutes. forum
  • Vs Dihexa: Cerebrolysin has far denser human RCT history; Dihexa is sold as more potent synaptogenic oral/topical research chem with almost no human trials. forum
  • Null / non-responders: Healthy users and some patients report no subjective change after a full cycle — authenticity, expectations, sleep, and injury vs healthy baseline are the usual post-mortems. forum
  • Lifestyle confound: Sleep, aerobic work, cognitive training, and concurrent peptides/nootropics often share credit in positive logs. forum
  • Post-stroke (clinical literature): Add-on IV courses studied for motor/functional recovery in acute/subacute ischemic stroke (e.g. multi-day 10–50 mL regimens in Cochrane-pooled trials). Effect sizes and mortality endpoints remain contested across reviews. trial
  • TBI (clinical literature): Multi-week IV courses discussed for moderate–severe TBI; CAPTAIN-style designs used high early doses then booster cycles with multidimensional outcome ensembles at day 10/30/90. trial
  • Vascular dementia scores: Cochrane vascular-dementia review and individual RCTs report modest cognitive-scale and daily-functioning shifts after series of daily infusions; heterogeneity of dose/duration is high. trial
  • Alzheimer’s / mixed dementia: Multi-week 10–30 mL cycles (often 5 days/week × ~4 weeks) appear in product dosage cards and older trials with modest cognitive-scale movement; not a disease-modifying claim in Western regulatory terms. trial
  • Neuroprotection frame: Community and preclinical language emphasize neuron survival, synaptic remodeling, and injury-model rescue after ischemia, trauma, or aging stress. animal
  • Animal / in-vitro anchors: Cholinergic rescue after fimbria-fornix lesion models, spatial-learning support, edema reduction after ischemia models, and EEG/functional changes in older volunteer/animal work are frequently cited in reviews. animal

Doses people talk about 19

  • Nootropic / biohack IM talk (pharma ampoules): Common forum band is ~5 mL/day IM (ampoule ceiling) or ~5–10 mL/day total when IV access is available; some start lower for tolerance. forum
  • Bryan Johnson–style public logs (community discussion): Cycles at ~5 mL and ~10 mL discussed for subjective clarity; hard to isolate objective gains. forum
  • Titration logs (Ever Pharma ampoules): Examples include 1 mL IM 5-on/2-off × ~2 weeks for tolerance, then ~5 mL IM 5-on/2-off × ~4 weeks. anecdote
  • Do not mix the two scales: Clinical mL ampoule math ≠ research-powder mg charts. Forum consensus: cerebroprotein hydrolysate powders are not proven identical to branded Cerebrolysin liquid. forum
  • Authenticity: Counterfeit, mislabeled, or substituted ampoules outside regulated pharmacy channels are a recurring risk theme. forum
  • Concentration anchor (clinical liquid): 1 mL contains 215.2 mg Cerebrolysin concentrate in aqueous solution — mL is the clinical unit; mg = mL × 215.2 for that product only. trial
  • Ampoule sizes discussed: 1 mL, 2 mL, 5 mL, 10 mL ampoules common; 30 mL multi-dose vials also appear in supply talk. trial
  • IV undiluted slow push: Up to ~10 mL undiluted IV, slow (~over ~3 minutes in the same guides). trial
  • IV infusion (larger volumes): ~10–50 mL (and some trial arms up to ~60 mL/day class) diluted to at least ~100 mL total volume with 0.9% NaCl, Ringer’s, or 5% glucose; infused promptly (product text often “within 15 minutes”; other clinical summaries describe ~15–60 minute infusions). trial
  • Stroke (product dosage card): ~20–50 mL/day, start ASAP, course ~10–21 days. trial
  • TBI (product dosage card): ~20–50 mL/day, start ASAP, course ~7–30 days (some card variants list slightly different day ranges). trial
  • Cognition problems / Alzheimer’s (product dosage card): ~10–30 mL/day; 1 cycle = 5 days weekly for 4 weeks; often 2–4 cycles per year. trial
  • Mild / lower clinical bands (secondary clinical summaries): ~1–5 mL discussed for milder cases; ~5–30 mL/24 h for dementia-type use; ~10–60 mL/24 h for severe stroke/TBI-type use in some hospital summaries. trial
  • Cochrane-style stroke arms (examples): Daily IV ~10 mL, ~30 mL, or ~50 mL for ~10 days (and some 50 mL × 21 days arms) appear in pooled acute ischemic stroke reviews. trial
  • CASTA-class stroke example: ~30 mL/day IV for ~10 days is a frequently cited large-trial pattern. trial
  • CAPTAIN-style TBI multi-cycle example: Cycle 1 days 1–10 at ~50 mL/day IV; cycle 2 days 31–40 at ~10 mL/day; cycle 3 days 61–70 at ~10 mL/day (diluted in ~250 mL 0.9% NaCl in published descriptions). trial
  • Amantadine combo research example: Clinical trial designs have used e.g. 50 mL/day days 1–10 then 20 mL-class later blocks diluted in saline — clinical co-study context, not a casual home stack. trial
  • Framing: Discussed ranges from product dosage cards, trials, and communities for research education only — not advice, prescriptions, or self-injection instructions. forum
  • IM undiluted ceiling: Product how-to guides cap a single undiluted IM injection at up to ~5 mL, injected slowly (~over ~3 minutes in label-style text). trial

How it may feel 8

  • Days 1–3: Commonly flat subjectively; mild headache, sweatiness, restlessness, or injection-site soreness possible; no classic same-day stimulant “on.” forum
  • Week 1: Daily or 5-on/2-off courses underway; subtle clarity for some, nothing for others; tolerance check for agitation/heat/sleep. forum
  • Post-cycle 1–4 weeks: Lingering ease of cognition for some; others lose the edge when daily shots stop — self-report only. anecdote
  • No change after a full cycle: Forums advise rechecking sleep, authenticity (EVER liquid vs powder), route/volume, and expectations — not auto-escalating into unsupervised high-volume IV. forum
  • Injection day 0–hours: Usually uneventful systemically if volume/rate are within label-style limits; site warmth, flush, or lightheadedness more likely if pushed too fast (especially IV). trial
  • Weeks 2–4: Main community and dementia-style checkpoint (e.g. 5 days/week × ~4 weeks); memory/clarity claims most often placed here rather than day one. trial
  • Acute neuro courses (10–21 days): Stroke/TBI trial windows are shorter and higher-volume; functional endpoints tracked at fixed days (e.g. day 10/30/90 in multi-cycle TBI designs), not “feel it this afternoon.” trial
  • Months 2–6 / pulsed year: 2–4 cognition cycles per year is the product-card pattern for chronic cognitive use; community re-runs when fog or demand returns. trial

Around the dose 3

  • Clock: Morning or split AM/PM in nootropic recovery charts. Night exists; some report vivid dreams. forum
  • Learning: People who want a cognitive story often add actual practice (language, music, rehab drills) during the course. forum
  • After: Sleep and not stacking five other CNS peptides on day one. forum

Cycles people discuss 8

  • Nootropic re-runs: Community often restarts when fog, heavy cognitive load, or perceived plateau returns rather than a fixed medical calendar. forum
  • Off-period honesty: Forum charts and pulsed use ≠ long-term safety data for unsupervised open-ended daily self-administration. forum
  • Acute stroke courses: Daily dosing ~10–21 days (product card often 10–21; trial arms commonly ~10 days). trial
  • Acute / subacute TBI courses: Daily dosing roughly ~7–30 days on product cards; multi-cycle booster designs also studied. trial
  • CAPTAIN multi-cycle pattern: High-dose first 10 days → rest → two later 10-day lower-dose boosters (~days 31–40 and 61–70). trial
  • Dementia / cognition cycles: ~4-week blocks, frequently 5 days on / weekend off, then rest; product card cites 2–4 cycles per year. trial
  • Avoid forever-daily without indication: Clinical model is short courses or cycled blocks, not indefinite daily home use. trial
  • Annual pulses (chronic cognitive framing): 2–4 cycles/year is the manufacturer-style rhythm for ongoing cognitive impairment talk. trial

Timing 7

  • Plasticity lag narrative: Short circulating presence of peptide fragments vs longer repair/remodeling processes after a course is the usual community explanation for delayed or post-course benefits. forum
  • Clock time: Morning vs evening debated; little controlled healthy-cognition timing data. Late-day stimulation/agitation reports push some toward earlier administration. forum
  • No single half-life: Multi-peptide + free amino acid mixture; components clear on different timescales — product literature does not market one neat t½ like a mono-peptide. trial
  • Why daily courses: Schedules assume once-daily (or multi-day-block) administration during a course, not a weekly depot peptide. trial
  • Infusion logistics: Higher IV volumes need dilution + controlled delivery; rapid push is linked to heat/dizziness. trial
  • Open ampoule rule: Administer promptly after opening; product text frames opened material as single-use, not multi-day multi-dose stock. trial
  • Start infusion promptly after dilution: Manufacturer handling notes emphasize beginning infusion soon after drawing/diluting and using disposable one-way sets. trial

More on what it is 6

  • Why people use it: Real hospital drug in many countries for stroke, TBI, vascular dementia, and Alzheimer’s-type dementia that crossed into LongeCity/biohack/nootropic circles for multi-week “brain repair” courses. forum
  • Supply reality: True clinical product is sealed liquid ampoules/vials (commonly 1 / 2 / 5 / 10 mL ampoules; larger multi-dose vials also discussed). Lyophilized “60 mg Cerebrolysin” research powders and Chinese cerebroprotein hydrolysates are a different scale and often a different product class — forums repeatedly warn they are not interchangeable with EVER Pharma liquid. forum
  • Mechanism talk: Framed as multimodal neurotrophic-factor–like fragments (BDNF/NGF/GDNF/CNTF-style narrative), synaptic plasticity support, anti-excitotoxic / anti-apoptotic protection, and metabolic support from the free-amino-acid fraction (~¾ free AAs / ~¼ peptide fraction in manufacturer-style descriptions). trial
  • Evidence base: Large human RCT and Cochrane literature in stroke and dementia plus TBI programs (e.g. CAPTAIN multi-cycle TBI design); absolute effect sizes and Western guideline status remain debated. trial
  • Not: Not one pure synthetic peptide, not an oral-by-design nootropic, not Semax/Selank, not Dihexa, not FDA-approved in the United States. trial
  • Regulatory snapshot: Prescription medicine in many European, Asian, and other markets for cerebrovascular / dementia indications; not FDA-registered for sale in the U.S. trial

Stacks 11

  • Semax: Acute nasal cognitive edge + Cerebrolysin multi-week neurotrophic/repair course — one of the most common dual frames. forum
  • Selank: Stress/mood/anxiolytic nasal support stacked with Cerebrolysin’s repair narrative. forum
  • Semax + Selank + Cerebrolysin: “Structural repair + performance + calm” triple often marketed in clinic-style nootropic stacking guides. forum
  • Dihexa: Sometimes sequenced or co-logged in advanced neurogenesis threads; sparse controlled combo data; Dihexa’s human evidence is far thinner. forum
  • P21 / Pinealon: Occasional advanced peptide-circle co-mentions for cognitive/aging frames — mostly anecdote. forum
  • NAD+ / mitochondrial support: Biohack stacks pair systemic NAD+ talk with Cerebrolysin’s neurotrophic frame. forum
  • BPC-157: Gut-brain / systemic recovery co-logging appears in some protocols; different primary indications and evidence bases. forum
  • Lifestyle co-factors: Sleep, aerobic exercise, and deliberate cognitive training frequently share credit for positive outcomes in community logs. forum
  • Avoid kitchen-sink overstacking: Concurrent stimulants, multiple uncharacterized injectables, and polypharmacy make single-agent credit and side-effect attribution unreliable. forum
  • Amantadine: Clinical co-study interest in neuro recovery (e.g. TBI-oriented trial designs) — not a casual home peptide stack. trial
  • rTMS / rehab modalities: Research protocols have combined Cerebrolysin courses with neuromodulation or standard rehab — clinical setting only. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 18

  • Porcine source / QC: Animal-brain origin implies theoretical contamination/QC risk; regulated pharmacy product ≠ gray-market unknown. forum
  • Fakes / substitutions: Counterfeit ampoules and mislabeled cerebroprotein powders sold as “Cerebrolysin” are a major community caution. forum
  • Injection technique risks: Infection, abscess, nerve injury, hematoma; IV adds air-embolism and line-infection risks if technique is poor. forum
  • Interactions map is thin: Weak systematic interaction data vs psych meds, anticoagulants, and polypharmacy stacks people discuss online. forum
  • Common (clinical/label-style): Headache, dizziness, nausea, sweating — usually described as transient and mild. trial
  • Local injection reactions: Pain, swelling, redness, warmth, flush — more likely if volume is large or delivery is too fast. trial
  • Agitation / heat / restlessness: Transient anxiety, agitation, feeling hot, or mild feverish sensation appear in product and secondary safety lists. trial
  • GI: Nausea, vomiting, indigestion, diarrhea listed in secondary drug summaries. trial
  • CNS / systemic: Tremor, mild fever, chills, sleepiness/dizziness affecting alertness; rare irregular heartbeat mentions in secondary lists. trial
  • Seizure risk / epilepsy: Product contraindications include epilepsy / major seizure disorders — risk of increasing seizure frequency is the stated concern. trial
  • Severe renal impairment: Listed contraindication on product materials. trial
  • Hypersensitivity / anaphylaxis: Porcine-tissue product — allergy to components is a contraindication; rare severe hypersensitivity/anaphylaxis case reports exist. trial
  • Pregnancy / lactation: Safety not established; product materials advise avoiding use. trial
  • Fast IV rate: Heat, lightheadedness, and flushing when pushed too quickly — primary practical reason for slow push/infusion. trial
  • Mixing ban: Product handling forbids mixing with vitamins, amino-acid solutions, and cardiovascular drugs in the same infusion — concurrent administration must be separate lines/times. trial
  • Driving / machinery: Dizziness or reduced alertness warnings appear in secondary patient leaflets. trial
  • Evidence honesty on safety: Large trial and pharmacovigilance experience often reports adverse-event rates comparable to placebo for common mild events, but that does not make unsupervised self-IV risk-free. trial
  • Regulatory: Approved in many countries for cerebrovascular/dementia-type use under medical supervision; not FDA-approved in the U.S. — research/education framing only for U.S. discussions. trial

Updated: 2026-08-21

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →